OPSENS ANNOUNCES ENTRY INTO STRUCTURAL HEART MARKET

Publisher: The Insight Partners

Opsens Inc. (“Opsens” or the “Company”) makes  announcment regarding it is expanding its medical device business into the structural cardiology space and will accelerate development activities of products that reach beyond its current coronary and peripheral applications.

Louis Laflamme, President and Chief Executive Officer commented, “Opsens’ technical and commercial capabilities have expanded over the last few years, fueled by our success in the coronary market. Our flagship product, the OptoWire, has been used in more than 80,000 patients in the United States, Europe, Japan, and Canada. We remain excited about our core business outlook and also see a highly synergistic adjacent market to expand our technology.”

The initial area of focus is aortic stenosis, a common and serious valve disease that is often treated through Trans Aortic Valve Replacement (TAVR). This is the fastest growing part of structural cardiology, driven by an aging population and advancements in valve technology and technique that are bringing the procedure to a wider patient population.

“The company has recently been successfully working on this structural heart project and has sufficiently advanced the program to warrant further activities and investment to accelerate our time to market. We plan to build on our existing technology, infrastructure and know-how in complementary directions,” Laflamme added. “We expect a number of positive development milestones in the next four to six quarters on our way to a commercially viable product that can have an immediate impact on TAVR procedures.”